Antibiotice
Antibiotice S.A., a prominent player in the pharmaceutical industry, is headquartered in Iaşi, Romania. Established in 1955, the company has evolved into a leading manufacturer of generic antibiotics and other essential medications, serving both domestic and international markets. With a strong focus on research and development, Antibiotice has achieved significant milestones, including the production of innovative formulations and a robust portfolio of over 200 products. The company’s core offerings include injectable antibiotics, oral medications, and topical treatments, distinguished by their high quality and efficacy. Antibiotice is recognised for its commitment to sustainability and compliance with international standards, positioning itself as a trusted partner in healthcare. With a solid market presence in Europe and beyond, Antibiotice continues to contribute to global health through its dedication to pharmaceutical excellence.
DitchCarbon Score
How does Antibiotice's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Antibiotice's score of 33 is higher than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Antibiotice's reported carbon emissions
In 2024, Antibiotice reported total carbon emissions of approximately 94,954,410 kg CO2e, comprising 9,495,410 kg CO2e from Scope 1, 3,589,130 kg CO2e from Scope 2, and a significant 73,014,390 kg CO2e from Scope 3 emissions. The Scope 1 emissions included 798,110 kg CO2e from mobile combustion and 8,620,690 kg CO2e from stationary combustion. Antibiotice has set ambitious climate commitments, aiming for a 46% reduction in greenhouse gas emissions from its operations (Scope 1 and 2) by 2030, using 2019 as the baseline year. This commitment reflects the company's proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. The company has consistently disclosed its emissions data, with a focus on transparency and accountability. In previous years, emissions were reported as follows: 9,937,240 kg CO2e in 2022, 11,391,000 kg CO2e in 2021, and 10,943,800 kg CO2e in 2020 for Scope 1. The data indicates a trend of increasing emissions, particularly in Scope 3, which highlights the importance of addressing supply chain impacts. Antibiotice's climate initiatives are not cascaded from a parent company, indicating an independent commitment to sustainability. The company is actively engaged in reducing its carbon footprint and aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 10,417,990 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,296,330 | - | - | - | 0,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Antibiotice is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
